Kevin R. Roy

Kevin R. Roy

Auto-generated profile, based on publicly available information

Kevin R. Roy

Stanford Genome Technology Center, Stanford University, Palo Alto, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2018 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
KRKevin R Roy
Kevin R Roy
JSJustin D Smith
Justin D Smith
SVSibylle C Vonesch
Sibylle C Vonesch
GLGen Lin
Gen Lin
CTChelsea Szu Tu
Chelsea Szu Tu
LSLars M Steinmetz
Lars M Steinmetz

18 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMTakeshi Matsui
Takeshi Matsui
MMMartin N. Mullis
Martin N. Mullis
KRKevin R. Roy
Kevin R. Roy
JHJoseph J. Hale
Joseph J. Hale
RSRachel Schell
Rachel Schell
IEIan M. Ehrenreich
Ian M. Ehrenreich
In diploid species, genetic loci can show additive, dominance, and epistatic effects. To characterize the contributions of these different types of genetic effects to heritable traits, we use a double barcoding system to generate and phenotype a panel of ~200,000 diploid yeast strains that can be partitioned into hundreds of interrelated families. This experiment enables the detection of thousands of epistatic loci, many whose effects vary across families. Here, we show traits are largely specified by a small number of hub loci with major additive and dominance effects, and pervasive epistasis. Genetic background commonly influences both the additive and dominance effects of loci, with multiple modifiers typically involved. The most prominent dominance modifier in our data is the mating locus, which has no effect on its own. Our findings show that the interplay between additivity, dominance, and epistasis underlies a complex genotype-to-phenotype map in diploids.

29 January 2016 in RNA
Verified
Journal Article
Open access
PDF file
QAQais Al-Hadid
Qais Al-Hadid
KRKevin Roy
Kevin Roy
GCGuillaume Chanfreau
Guillaume Chanfreau
SCSteven G. Clarke
Steven G. Clarke
Rpl3, a highly conserved ribosomal protein, is methylated at histidine 243 by the Hpm1 methyltransferase in Saccharomyces cerevisiae. Histidine 243 lies close to the peptidyl transferase center in a functionally important region of Rpl3 designated as the basic thumb that coordinates the decoding, peptidyl transfer, and translocation steps of translation elongation. Hpm1 was recently implicated in ribosome biogenesis and translation. However, the biological role of methylation of its Rpl3 substrate has not been identified. Here we interrogate the role of Rpl3 methylation at H243 by investigating the functional impact of mutating this histidine residue to alanine (rpl3-H243A). Akin to Hpm1-deficient cells, rpl3-H243A cells accumulate 35S and 23S pre-rRNA precursors to a similar extent, confirming an important role for histidine methylation in pre-rRNA processing. In contrast, Hpm1-deficient cells but not rpl3-H243A mutants show perturbed levels of ribosomal subunits. We show that Hpm1 has multiple substrates in different subcellular fractions, suggesting that methylation of proteins other than Rpl3 may be important for controlling ribosomal subunit levels. Finally, translational fidelity assays demonstrate that like Hpm1-deficient cells, rpl3-H243A mutants have defects in translation elongation resulting in decreased translational accuracy. These data suggest that Rpl3 methylation at H243 is playing a significant role in translation elongation, likely via the basic thumb, but has little impact on ribosomal subunit levels. Hpm1 is therefore a multifunctional methyltransferase with independent roles in ribosome biogenesis and translation.

11 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GNGernot Neumayer
Gernot Neumayer
JTJessica L. Torkelson
Jessica L. Torkelson
SLShengdi Li
Shengdi Li
KMKelly McCarthy
Kelly McCarthy
HZHanson H. Zhen
Hanson H. Zhen
AOAnthony E. Oro
Anthony E. Oro
We present Dystrophic Epidermolysis Bullosa Cell Therapy (DEBCT), a scalable platform producing autologous organotypic iPS cell-derived induced skin composite (iSC) grafts for definitive treatment. Clinical-grade manufacturing integrates CRISPR-mediated genetic correction with reprogramming into one step, accelerating derivation of COL7A1-edited iPS cells from patients. Differentiation into epidermal, dermal and melanocyte progenitors is followed by CD49f-enrichment, minimizing maturation heterogeneity. Mouse xenografting of iSCs from four patients with different mutations demonstrates disease modifying activity at 1 month. Next-generation sequencing, biodistribution and tumorigenicity assays establish a favorable safety profile at 1-9 months. Single cell transcriptomics reveals that iSCs are composed of the major skin cell lineages and include prominent holoclone stem cell-like signatures of keratinocytes, and the recently described Gibbin-dependent signature of fibroblasts. The latter correlates with enhanced graftability of iSCs. In conclusion, DEBCT overcomes manufacturing and safety roadblocks and establishes a reproducible, safe, and cGMP-compatible therapeutic approach to heal lesions of DEB patients.

6 November 2017 in Transcription
Verified
Journal Article
Closed access
KRKevin Roy
Kevin Roy
GCGuillaume F. Chanfreau
Guillaume F. Chanfreau
The role of transcription factors (TFs) on nucleosome positioning, RNA polymerase recruitment, and transcription initiation has been extensively characterized. Here, we propose that a subset of TFs such as Reb1, Abf1, Rap1, and TFIIIB also serve a major function in partitioning transcription units by assisting the Nrd1p-Nab3p-Sen1p Pol II termination pathway.

1 July 2026 in Nature
Verified
Journal Article
Closed access
PDF file
LQLiujia Qian
Liujia Qian
ZZZizhuo Zhou
Zizhuo Zhou
PZPeijie Zhou
Peijie Zhou
ZDZhen Dong
Zhen Dong
XZXudong Zhang
Xudong Zhang
TGTiannan Guo
Tiannan Guo